Ropes & Gray Represents Chiesi Group in Collaboration with Gossamer Bio

Ropes & Gray advised Parma, Italy-based biopharmaceutical company Chiesi Group in a global strategic collaboration with Gossamer Bio to develop and commercialize Gossamer’s pulmonary arterial hypertension treatment seralutinib. The transaction was announced on May 6.

Under the agreement, Gossamer will lead the global development of seralutinib in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Gossamer will receive $160 million in development reimbursement payment and is eligible to receive up to $146 million in regulatory and $180 million in sales milestones. In the U.S., the companies will evenly share commercial profits and losses. Chiesi will have the exclusive right to commercialize seralutinib outside of the U.S. and will pay Gossamer an escalating mid-to-high teens royalty on net sales outside of the U.S.

The Ropes & Gray team was led by life sciences licensing partner Amanda Austin and life sciences licensing associate Nicole Rohr and included life sciences licensing and emerging companies and venture capital partner Marc Rubenstein, life sciences regulatory & compliance partner Kellie Combs, tax partner David Saltzman, emerging companies and venture capital counsel Ray Grant and litigation & enforcement counsel Deidre Johnson.